WHY: Seven point four (7.4) million Americans of all ages have Alzheimer’s disease or other dementias (2025 Alzheimer’s Disease Facts and Figures, 2025). Age is by far the greatest risk factor. One in nine individuals over 65 and 35.8% of those over 85 are affected (2025 Alzheimer’s Disease Facts and Figures, 2025). The population, 65 years and older, is anticipated to grow from 65 million in 2026 to 82 million by the year 2050 (2025 Alzheimer’s Disease Facts and Figures, 2025).  The actual incidence rate of Alzheimer’s and related dementias has declined secondary to the identification and implementation of modifiable risk factors for dementia, which include general population educational levels, in addition to better management of chronic diseases such as hypertension, coronary/vascular disease and diabetes management. However, the increasing numbers of older adults will result in increased numbers of those with Alzheimer’s and related dementias. The increased availability of successful new pharmacologic interventions for dementia and dementia-related illnesses means there is a substantial need for increased early identification of cognitive impairment, particularly in the older adult population. Using a reliable and valid tool that clinicians can quickly implement facilitates early identification and allows the person to receive prompt treatment. Early identification and intervention in the form of medication and behavioral therapy may slow disease progression, delay functional decline, allow for pre-planning, and postpone nursing home placement. Whereas the U.S. Preventative Services Task Force (USPSTF, 2020) does not recommend routine cognitive screening in asymptomatic community-dwelling older adults, the Alzheimer’s Association and the American Geriatrics Society do recommend incorporation of assessment of cognitive impairment into the Medicare AWV. The Centers for Medicare & Medicaid Services has included routine cognitive screening as a required component of the Medicare Annual Wellness Visit (AWV) (CMS.Gov, 2025). The Mini-CogTM is one of three tools endorsed by the Alzheimer’s Association for use in the Medicare AWV. 

BEST TOOL: The Mini-CogTM is a simple screening tool that is well accepted and takes up to only 3 minutes to administer. This tool can be used to detect cognitive impairment quickly during both routine visits and hospitalizations. The Mini-CogTM serves as an effective triage tool to identify individuals in need of more thorough evaluation. The Clock Drawing Test (CDT) component of the Mini-CogTM allows clinicians to quickly assess numerous cognitive domains including cognitive function, memory, language comprehension, visual-motor skills, and executive function and provides a visible record of both normal and impaired performance that can be tracked over time.

TARGET POPULATION: The Mini-CogTM is appropriate for use in all health care settings.  It is appropriate to be used with older adults at various heterogeneous language, culture, and literacy levels.

VALIDITY AND RELIABILITY: The Mini-CogTM was developed as a brief screening tool to differentiate patients with dementia from those without dementia. Depending on the prevalence of dementia in the target population, the Mini-CogTM has sensitivity ranging from 76-100%, and specificity ranging from 76-100% with 95% confidence interval. A chi-square test reported 234.4 for Alzheimer’s dementia and 118.3 for other dementias (p<0.001) (Stewart, C., Stewart, J., Stubbs, S.,Epline, J. (2022). This tool has strong predictive value in multiple clinical settings (Yang, Q., Yang, H., Long, W., Zuo, S., Guo, Q. (2025). Research suggests that a 5-point numerical scoring system based on the original algorithm may be easier to apply: repeating three items (0 points), a clock drawing distractor (CDT) (0-2 points), and recall of the earlier three items after the CDT (0-3 points). A score of 0-2 out of 5 is a positive screen for dementia, 3-5 out of 5 is a negative screen for dementia (Stewart, C., Stewart, J., Stubbs, S., Epline, J., 2022), but a cut score of 4-5 out of 5 may increase detection of mild cognitive impairment (McCarten et al., 2012). The Mini-CogTM alone is not considered a valid tool for this use. Further assessment of mild cognitive impairment may be completed by administering the Montreal Cognitive Assessment (MoCA) (See Try this:® MoCA).

STRENGTHS AND LIMITATIONS: The Mini-CogTM takes up to 3 minutes to administer. The clock drawing component of the test is scored simply as normal or abnormal for the purpose of the Mini-CogTM and specific scoring rules are included with the tool. More comprehensive analysis of the CDT does not improve detection of dementia and would increase complexity of the currently simple training requirements for clinicians and perhaps decrease its attractiveness as a simple screening tool. The Mini-CogTM is not strongly influenced by education, culture, or language; it was perceived as less stressful to the individual than other longer mental status tests. The accuracy of the Mini-CogTM in heterogeneous groups may increase the identification of dementia in populations less diagnosed, thereby increasing minority participation in research and improving parity of early treatment. 

MORE ON THE TOPIC:

Alzheimer’s Association. 2026 Alzheimer’s Disease Facts and Figures. Alzheimer's Dementia 2026;22. https://doi.org/10.1002/alz.71345.

Cognitive Assessment, (2026). Cognitive Assessment & Care Plan Services. Centers for Medicare and Medicaid Services, 

Cognitive Impairment in Older Adults: Screening, (2020) .U.S. Preventative Services Task Force. 2020 (currently under revision 2026)

Stewart, C., Stewart, J., Stubbs, S.,Epline, J. (2022).Mini-Cog, IQCODE, MoCA, and MMSE for the Prediction of Dementia in Primary Care.  American Family Physician. 

Yang, Q., Yang, H., Long, W., Zuo,S., Guo, Q. (2025). Rapid Cognitive Assessment: Accuracy and Discriminant validity of Mini-Cog and process Based Clock Drawing Test. Journal of Alzheimer Disease.